[
    [
        {
            "time": "",
            "orginal_text": "医药行业2018年报及2019年一季报综述：2018Q4利润增速承压，医药子行业持续分化",
            "features": {
                "keywords": [
                    "医药行业",
                    "2018年报",
                    "2019一季报",
                    "利润增速",
                    "子行业分化"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "医药行业2018年报及2019年一季报综述：2018Q4利润增速承压，医药子行业持续分化",
            "scores": {
                "News_content": "医药行业2018年报及2019年一季报综述：2018Q4利润增速承压，医药子行业持续分化",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "orginal_text": "上交所12问康美药业！近300亿元如何“失踪”？开尔新材半年报预增90倍；广州浪奇发力工业大麻应用；两公司遭立案调查",
            "features": {
                "keywords": [
                    "康美药业",
                    "财务问题",
                    "开尔新材",
                    "半年报预增",
                    "工业大麻",
                    "立案调查"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "工业大麻"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "上交所12问康美药业！近300亿元如何“失踪”？开尔新材半年报预增90倍；广州浪奇发力工业大麻应用；两公司遭立案调查",
            "scores": {
                "News_content": "上交所12问康美药业！近300亿元如何“失踪”？开尔新材半年报预增90倍；广州浪奇发力工业大麻应用；两公司遭立案调查",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 10,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "A股药企年报季结束，哪些高管、员工薪酬较高？",
            "features": {
                "keywords": [
                    "A股药企",
                    "年报",
                    "高管薪酬",
                    "员工薪酬"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "original_text": "A股药企年报季结束，哪些高管、员工薪酬较高？",
            "scores": {
                "News_content": "A股药企年报季结束，哪些高管、员工薪酬较高？",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 5,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "orginal_text": "A股疫苗龙头研发投入PK！哪些重磅疫苗最值得期待？",
            "features": {
                "keywords": [
                    "A股疫苗",
                    "研发投入",
                    "重磅疫苗"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "A股疫苗龙头研发投入PK！哪些重磅疫苗最值得期待？",
            "scores": {
                "News_content": "A股疫苗龙头研发投入PK！哪些重磅疫苗最值得期待？",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "orginal_text": "最新药审动态：复星又来重磅抗癌生物类似药 3个亿级产品通过评",
            "features": {
                "keywords": [
                    "复星",
                    "抗癌生物类似药",
                    "药审动态",
                    "亿级产品"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "抗癌药物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "最新药审动态：复星又来重磅抗癌生物类似药 3个亿级产品通过评",
            "scores": {
                "News_content": "最新药审动态：复星又来重磅抗癌生物类似药 3个亿级产品通过评",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "复星旅文飙近6%兼破顶 两日暂累升10.3%",
            "features": {
                "keywords": [
                    "复星旅文",
                    "股价上涨",
                    "累计涨幅"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "旅游"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "复星旅文飙近6%兼破顶 两日暂累升10.3%",
            "scores": {
                "News_content": "复星旅文飙近6%兼破顶 两日暂累升10.3%",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 6,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "6日公司新闻聚焦：康美药业遭监管问询 广州浪奇发力工业大麻应用",
            "features": {
                "keywords": [
                    "康美药业",
                    "监管问询",
                    "广州浪奇",
                    "工业大麻"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "工业大麻"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "6日公司新闻聚焦：康美药业遭监管问询 广州浪奇发力工业大麻应用",
            "scores": {
                "News_content": "6日公司新闻聚焦：康美药业遭监管问询 广州浪奇发力工业大麻应用",
                "Correlation": 8,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "orginal_text": "【医药-复星医药(600196)】江琦、赵磊：2019Q1点评：持续加大研发投入，归母净利润企稳小幅增长0.92%-0429",
            "features": {
                "keywords": [
                    "复星医药",
                    "研发投入",
                    "归母净利润",
                    "小幅增长"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "【医药-复星医药(600196)】江琦、赵磊：2019Q1点评：持续加大研发投入，归母净利润企稳小幅增长0.92%-0429",
            "scores": {
                "News_content": "【医药-复星医药(600196)】江琦、赵磊：2019Q1点评：持续加大研发投入，归母净利润企稳小幅增长0.92%-0429",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "“最贵董事长”易主 11名高管薪酬超千万",
            "features": {
                "keywords": [
                    "董事长",
                    "高管薪酬",
                    "超千万"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "企业管理"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "original_text": "“最贵董事长”易主 11名高管薪酬超千万",
            "scores": {
                "News_content": "“最贵董事长”易主 11名高管薪酬超千万",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]